Trial
NCT00449150
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AEterna Zentaris
Collaborators
—
Condition
Benign Prostatic Hypertrophy
Intervention
Cetrorelix 78 mg + 78 mg
Why stopped
Trial did not meet primary efficacy endpoint for double blind phase.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-03